Moleculin Biotech CS (MBRX)

$0.67 +0.04 (5.91%)
Market Cap 18.97M
Revenue (ttm) 0.00
Net Income (ttm) -21.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,134,000
Avg Vol 6,500,848
Day's Range N/A - N/A
Shares Out 30.21M
Stochastic %K 42%
Beta 1.38
Analysts Strong Sell
Price Target $7.00

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: (713) 300-5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
Zdxss1
Zdxss1 Aug. 1 at 7:47 PM
$MBRX Don't worry about pumping stocks and increasing the number of shares. The company owns a medicine with a future. Let me give you an example. This is IBRX, a company in the third phase. It has not yet been approved by the FDA. The number of shares in the company is 900 million shares. The share price is $2.4. The company MBRX has a better future than IBRX.
1 · Reply
Thyge
Thyge Aug. 1 at 6:03 PM
$MBRX this stock f*cking bipolar
1 · Reply
thazen
thazen Aug. 1 at 5:58 PM
$MBRX well that a new movement 🤷🤔
0 · Reply
thazen
thazen Aug. 1 at 5:00 PM
$MBRX WTF is the float gonna be after they are done adding all these shares?🫤
1 · Reply
dolfin20th
dolfin20th Aug. 1 at 4:45 PM
$MBRX ok. like it. go up.
0 · Reply
ShipIttwice
ShipIttwice Aug. 1 at 4:21 PM
$MBRX Slow and steady
0 · Reply
ShipIttwice
ShipIttwice Aug. 1 at 3:48 PM
$MBRX Okay, no more bashing..
0 · Reply
Zdxss1
Zdxss1 Aug. 1 at 1:26 PM
$MBRX This pig's posts are all bad.
0 · Reply
cheeseandsmile
cheeseandsmile Aug. 1 at 9:14 AM
$MBRX where are all these arab fake pumper accounts … bunch of Roth Capital corruption
0 · Reply
ShipIttwice
ShipIttwice Jul. 31 at 10:30 PM
$MBRX 😩😩😩😩
0 · Reply
Latest News on MBRX
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 30, 2025, 8:35 AM EDT - 2 days ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 10 days ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 17, 2025, 8:25 AM EDT - 15 days ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 9, 2025, 8:35 AM EDT - 23 days ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Top 3 Health Care Stocks You'll Regret Missing This Quarter

Jun 26, 2025, 8:15 AM EDT - 5 weeks ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

CPRX

Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 6 weeks ago

Moleculin Announces $5.9 Million Public Offering

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:45 AM EDT - 6 weeks ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 18, 2025, 7:30 AM EDT - 6 weeks ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 5, 2025, 8:00 AM EDT - 2 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 2 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:20 PM EDT - 2 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 2 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025, 8:40 AM EDT - 2 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025, 9:00 AM EDT - 3 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 6, 2025, 9:00 AM EDT - 3 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

May 5, 2025, 8:45 AM EDT - 3 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 29, 2025, 8:35 AM EDT - 3 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 17, 2025, 8:30 AM EDT - 3 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Apr 1, 2025, 8:30 AM EDT - 4 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 10:50 AM EDT - 4 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 4 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 19, 2025, 8:05 AM EDT - 4 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 5 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 8:45 AM EDT - 5 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 6, 2025, 8:30 AM EST - 5 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Mar 3, 2025, 8:30 AM EST - 5 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 25, 2025, 12:35 PM EST - 5 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:19 PM EST - 6 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 1:05 PM EST - 6 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 13, 2025, 9:25 AM EST - 6 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Feb 11, 2025, 8:40 AM EST - 6 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 27, 2025, 8:30 AM EST - 6 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Jan 8, 2025, 8:30 AM EST - 7 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Dec 11, 2024, 8:00 AM EST - 8 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 18, 2024, 8:15 AM EST - 9 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 14, 2024, 8:15 AM EST - 9 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 12, 2024, 8:00 AM EST - 9 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 11:17 AM EST - 9 months ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 7:05 AM EST - 9 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Nov 5, 2024, 9:00 AM EST - 9 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Nov 4, 2024, 8:30 AM EST - 9 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Oct 17, 2024, 8:40 AM EDT - 10 months ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Oct 7, 2024, 8:30 AM EDT - 10 months ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Moleculin to Present at Two Upcoming Investor Conferences

Oct 4, 2024, 9:00 AM EDT - 10 months ago

Moleculin to Present at Two Upcoming Investor Conferences

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Sep 23, 2024, 8:00 AM EDT - 11 months ago

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Moleculin Participates in Virtual Investor "What this Means" Segment

Sep 16, 2024, 8:30 AM EDT - 11 months ago

Moleculin Participates in Virtual Investor "What this Means" Segment

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Sep 9, 2024, 8:15 AM EDT - 11 months ago

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 9:15 AM EDT - 11 months ago

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Aug 26, 2024, 8:30 AM EDT - 1 year ago

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Moleculin Announces Closing of up to $16.5 Million Public Offering

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Moleculin Announces Closing of up to $16.5 Million Public Offering

Zdxss1
Zdxss1 Aug. 1 at 7:47 PM
$MBRX Don't worry about pumping stocks and increasing the number of shares. The company owns a medicine with a future. Let me give you an example. This is IBRX, a company in the third phase. It has not yet been approved by the FDA. The number of shares in the company is 900 million shares. The share price is $2.4. The company MBRX has a better future than IBRX.
1 · Reply
Thyge
Thyge Aug. 1 at 6:03 PM
$MBRX this stock f*cking bipolar
1 · Reply
thazen
thazen Aug. 1 at 5:58 PM
$MBRX well that a new movement 🤷🤔
0 · Reply
thazen
thazen Aug. 1 at 5:00 PM
$MBRX WTF is the float gonna be after they are done adding all these shares?🫤
1 · Reply
dolfin20th
dolfin20th Aug. 1 at 4:45 PM
$MBRX ok. like it. go up.
0 · Reply
ShipIttwice
ShipIttwice Aug. 1 at 4:21 PM
$MBRX Slow and steady
0 · Reply
ShipIttwice
ShipIttwice Aug. 1 at 3:48 PM
$MBRX Okay, no more bashing..
0 · Reply
Zdxss1
Zdxss1 Aug. 1 at 1:26 PM
$MBRX This pig's posts are all bad.
0 · Reply
cheeseandsmile
cheeseandsmile Aug. 1 at 9:14 AM
$MBRX where are all these arab fake pumper accounts … bunch of Roth Capital corruption
0 · Reply
ShipIttwice
ShipIttwice Jul. 31 at 10:30 PM
$MBRX 😩😩😩😩
0 · Reply
cheeseandsmile
cheeseandsmile Jul. 31 at 6:38 PM
$MBRX Big TRADER_tom 😅 H&S formation in the house, Gap-Up will close 👇.40 Roth needs volume to place shares at the market and they got it. You have to ask you, why this comp published an intent of grant news. They have not yet published granted patent from this month.
0 · Reply
cheeseandsmile
cheeseandsmile Jul. 31 at 6:25 PM
$MBRX looks like T_T is a part of this paid pump Arabic Roth office … SEC is
0 · Reply
ShipIttwice
ShipIttwice Jul. 31 at 5:42 PM
$MBRX
0 · Reply
cheeseandsmile
cheeseandsmile Jul. 31 at 5:32 PM
$MBRX SEC account
0 · Reply
Trader_Tom
Trader_Tom Jul. 31 at 4:14 PM
$MBRX cheeseandsmile has a ST account opened years ago and dedicated to only MBRX. Kind of makes you ? what that account is for. 🤔
0 · Reply
ShipIttwice
ShipIttwice Jul. 31 at 4:10 PM
$MBRX hopefully rebound after lunch 😩😩😳
0 · Reply
cheeseandsmile
cheeseandsmile Jul. 31 at 3:37 PM
$MBRX ATM dilution and Roth actors (X+ST) supporting ATM program … can you feel corruption!!!
1 · Reply
Trader_Tom
Trader_Tom Jul. 31 at 2:41 PM
$MBRX Analyst like this @ $4 ...Adding the Analyst info on this post. Scalping $PAPL $SNGX $APLD $PBM
0 · Reply
EricKuoTW
EricKuoTW Jul. 31 at 1:13 PM
$MBRX Is there a chance to move up today?😩
1 · Reply
thazen
thazen Jul. 31 at 12:15 AM
$MBRX Well....Well....Well. 🥳💥 May the morning be with us fellow holders!
3 · Reply
ShipIttwice
ShipIttwice Jul. 30 at 8:24 PM
$MBRX Damn, I needed you guys to pump this trash, so I could get out 🤬🤬🤬🤬
0 · Reply
Hcrawford0732
Hcrawford0732 Jul. 30 at 5:29 PM
$MBRX still strong, could see this hitting .80-.85 today
1 · Reply